Shift in secretory profile of a pNET: from indolent glucagonoma to aggressive insulinoma - a case report. [PDF]
Gil Dos Santos S +4 more
europepmc +1 more source
Thymic Neuroendocrine Tumors: Evolving Insights and Innovative Approaches. [PDF]
Pietroluongo E +9 more
europepmc +1 more source
Expanding the therapeutic horizon of <sup>177</sup>Lu-DOTATATE: a review of current evidence. [PDF]
Minamimoto R +5 more
europepmc +1 more source
Lead radionuclides for theranostic applications in nuclear medicine: from atom to bedside. [PDF]
Berckmans Y +10 more
europepmc +1 more source
Radiation exposure to families of patients following administration of <sup>177</sup>Lu-DOTATATE for the treatment of metastatic neuroendocrine tumours. [PDF]
Levart D +4 more
europepmc +1 more source
Lutetium-177 DOTATATE for the Treatment of Esthesioneuroblastoma: A Case Report. [PDF]
Avila-Rodriguez V +9 more
europepmc +1 more source
Anatomical-biochemical discordance and prognostic role of bone metastases in advanced MTC treated with [¹⁷⁷Lu]Lu-DOTA-TATE. [PDF]
Bilgic S +3 more
europepmc +1 more source
Sequencing Choices and Real-World Clinical Management in Advanced Grade 2/3 GEP-NET Treatment: The Emerging Role of PRRT. [PDF]
Chauhan A +2 more
europepmc +1 more source
von Hippel-Lindau Disease Associated Pancreatic Neuroendocrine Tumors – Molecular Genetics and Clinical Aspects [PDF]
Birke Bausch, +6 more
core

